Trevi Therapeutics Reports Earnings Results

Trevi Therapeutics (NASDAQ:TRVI) released its earnings results on Tuesday. The company reported an earnings per share (EPS) of ($0.11) for the quarter, which was better than the analysts' consensus estimate of ($0.12) by $0.01, according to Zacks.

Trevi Therapeutics Stock Performance

On Tuesday, Trevi Therapeutics stock rose by 0.8%, increasing by $0.06 to reach $6.60 during mid-day trading. The trading volume was approximately 2,202,888 shares, significantly higher than the average volume of 968,847 shares. Trevi Therapeutics has a current market capitalization of $506.93 million and a price-to-earnings ratio of -14.99. The stock has experienced a 12-month low of $2.30 and a high of $7.39. Its fifty-day moving average stands at $4.39, while the 200-day moving average is $3.66.

Insider Transactions

In related news, insider Farrell Simon sold 81,313 shares of Trevi’s stock on Monday, March 10. The shares were sold at an average price of $6.75, resulting in a total transaction value of approximately $548,862.75. Following this sale, Simon now holds 76,900 shares in the company, valued at around $519,075. This transaction represented a 51.39% decrease in Simon's ownership of the stock. Details of this trade were disclosed to the Securities & Exchange Commission, which can be accessed through their website. Currently, insiders own 24.37% of the company's total stock.

Analyst Insights

Trevi Therapeutics has been the subject of multiple research reports. Recently, Oppenheimer raised their target price for the stock from $12.00 to $20.00 and gave it an "outperform" rating in a report dated March 11. HC Wainwright also increased their target price from $7.50 to $12.50 while issuing a "buy" rating in their analysis on March 10. Needham & Company LLC raised their price target from $8.00 to $25.00, maintaining a "buy" rating in their report on the same day. D. Boral Capital reiterated a "buy" rating with a target price of $21.00 in a note on March 7. Meanwhile, Raymond James upgraded Trevi Therapeutics from "outperform" to "strong-buy" and lifted their price target from $9.00 to $29.00 on March 10. Presently, seven research analysts have assigned the stock a "buy" rating, while three recommend a strong buy. According to data from MarketBeat, the average consensus rating for Trevi Therapeutics is "Buy" with a consensus price target of $15.94.

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and marketing therapy Haduvio. This treatment targets chronic cough conditions related to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), acting on both central and peripheral nervous systems.

Trevi, Therapeutics, Earnings